Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on TherapeuticsMD (TXMD) today and set a price target of $27. The company’s shares opened today at $5.11.
Chen noted:
“We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 5.4% and a 36.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on TherapeuticsMD is a Strong Buy with an average price target of $19, which is a 271.8% upside from current levels. In a report issued on January 23, Oppenheimer also assigned a Buy rating to the stock with a $14 price target.
See today’s analyst top recommended stocks >>
Based on TherapeuticsMD’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $35.61 million. In comparison, last year the company had a GAAP net loss of $21.43 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
